Methylome analysis in circulating tumor DNA to predict baseline or aquired sorafenib resistance in hepatocellular carcinoma patients

We aim to follow the DNA methylome in circulating tumor DNA of advanced HCC patients treated with sorafenib. This will be achieved using the SeqCapEpi platform. We will correlate the findings with previous in vitro results, engage in biomarker training and collect samples for validation.